What do systematic reviews say?

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 3 [0.39, 23.07]
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.3, 1.31]
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Moxifloxacin + SRP vs SRP

Moxifloxacin + SRP showed no clear difference in adverse events compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes
  The included trial (Ardila 2015) had no adverse events amongst the participants.
  1 study · 40 participants
  GRADE not reported

Moxifloxacin + SRP vs SRP

Moxifloxacin + SRP led to lower probing pocket depth compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -0.42 [-0.74, -0.10]
  1 study · 40 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -0.55 [-0.87, -0.23]
  1 study · 40 participants
  GRADE not reported

Moxifloxacin + SRP vs SRP

Moxifloxacin + SRP led to lower clinical attachment level (CAL) compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -0.67 [-1.01, -0.33]
  1 study · 40 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -0.63 [-0.95, -0.31]
  1 study · 40 participants
  GRADE not reported

Moxifloxacin + SRP vs SRP

Moxifloxacin + SRP led to lower percentage of bleeding on probing (BOP) compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -3.40 [-3.72, -3.08]
  1 study · 40 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -0.80 [-1.12, -0.48]
  1 study · 40 participants
  GRADE not reported

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).

• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
  RR 3.56 [2.37, 5.37]
  3 studies · 2265 participants
  Moderate

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
  RR 1.06 [0.65, 1.75]
  3 studies · 2760 participants
  Moderate

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).

• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
  RR 0.71 [0.33, 1.52]
  3 studies · 2282 participants
  Moderate

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).

• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
  RR 0.33 [0.08, 1.31]
  3 studies · 2282 participants
  Low

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes only
  RR 0.97 [0.74, 1.27]
  4 studies · 3548 participants
  Moderate

Intervention not reported

It is very uncertain whether the intervention changes moxifloxacin versus piperacillin/tazobactam followed by… (very low certainty).

• Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) in non surgical wounds 2013 · Cochrane Headline outcomes only
  RR 0.87 [0.56, 1.36]
  1 study · 23 participants
  Very low